153 related articles for article (PubMed ID: 26332209)
1. Active surveillance in localized prostate cancer: comparison of incidental tumours (T1a/b) and tumours diagnosed by core needle biopsy (T1c/T2a): results from the HAROW study.
Herden J; Wille S; Weissbach L
BJU Int; 2016 Aug; 118(2):258-63. PubMed ID: 26332209
[TBL] [Abstract][Full Text] [Related]
2. Active Surveillance for Incidental (cT1a/b) Prostate Cancer: Long-Term Outcomes of the Prospective Noninterventional HAROW Study.
Herden J; Schwarte A; Boedefeld EA; Weissbach L
Urol Int; 2021; 105(5-6):428-435. PubMed ID: 33517336
[TBL] [Abstract][Full Text] [Related]
3. HAROW: the first comprehensive prospective observational study comparing treatment options in localized prostate cancer.
Weissbach L; Stuerzebecher S; Mumperow E; Klotz T; Schnell D
World J Urol; 2016 May; 34(5):641-7. PubMed ID: 26373955
[TBL] [Abstract][Full Text] [Related]
4. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
Herden J; Weissbach L
World J Urol; 2018 Mar; 36(3):383-391. PubMed ID: 29330583
[TBL] [Abstract][Full Text] [Related]
5. Risk stratification: a tool to predict the course of active surveillance for localized prostate cancer?
Herden J; Heidenreich A; Weissbach L
BJU Int; 2017 Aug; 120(2):212-218. PubMed ID: 27862832
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and treatment of T1a-T1b prostate cancer].
Liu Z; Luo C; Hu S; Fan Y; Liu ZH; Yang XY; Shen Q; Liu LB; Han WK; Zhou LQ; Yu W; He Q; Zhang Q; Jin J
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 48(5):812-816. PubMed ID: 27752161
[TBL] [Abstract][Full Text] [Related]
7. Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies.
Luzzago S; Piccinelli ML; Marvaso G; Laukhtina E; Miura N; Schuettfort VM; Mori K; Aydh A; Ferro M; Mistretta FA; Fusco N; Petralia G; Jereczek-Fossa BA; Shariat SF; Karakiewicz PI; de Cobelli O; Musi G
World J Urol; 2022 Feb; 40(2):443-451. PubMed ID: 34687344
[TBL] [Abstract][Full Text] [Related]
8. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
10. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.
Koie T; Mitsuzuka K; Narita S; Yoneyama T; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C
Scand J Urol; 2015 Apr; 49(2):103-7. PubMed ID: 25165894
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Incidental Prostate Cancer by Active Surveillance: Results of the HAROW Study.
Herden J; Eminaga O; Wille S; Weissbach L
Urol Int; 2015; 95(2):209-15. PubMed ID: 26044747
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting).
Ansmann L; Winter N; Ernstmann N; Heidenreich A; Weissbach L; Herden J
BJU Int; 2018 Sep; 122(3):401-410. PubMed ID: 29603553
[TBL] [Abstract][Full Text] [Related]
13. Retrospective study of 101 cases with incidental prostate cancer stages T1a and T1b.
Masue N; Deguchi T; Nakano M; Ehara H; Uno H; Takahashi Y
Int J Urol; 2005 Dec; 12(12):1045-9. PubMed ID: 16409608
[TBL] [Abstract][Full Text] [Related]
14. [Incidental prostatic cancer: T1a-T1b. Our experience after observation/radical surgery and literature review].
Allué López M; Allepuz Losa C; Borque Fernando A; Serrano Frago P; Gil Martínez P; Gil Sanz MJ; Rioja Sanz LA
Actas Urol Esp; 2006 Sep; 30(8):749-53; discussion 753. PubMed ID: 17078571
[TBL] [Abstract][Full Text] [Related]
15. Incidental Prostate Cancer Diagnosis During Holmium Laser Enucleation: Assessment of Predictors, Survival, and Disease Progression.
Elkoushy MA; Elshal AM; Elhilali MM
Urology; 2015 Sep; 86(3):552-7. PubMed ID: 26216838
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
17. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease.
Helfand BT; Mongiu AK; Kan D; Kim DY; Loeb S; Roehl KA; Meeks JJ; Smith ND; Catalona WJ
BJU Int; 2009 Aug; 104(3):304-9. PubMed ID: 19239451
[TBL] [Abstract][Full Text] [Related]
19. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
Epstein JI; Walsh PC; Carmichael M; Brendler CB
JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
[TBL] [Abstract][Full Text] [Related]
20. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
